Benign prostatic hyperplasia (BPH) is a common clinical disorder in elderly males. It causes a variety of urological symptoms, including a poor stream of urine flow, dribbling and nocturia. Adrenergic a-receptors are the molecular target for the clinical treatment of arterial hypertension and benign prostatic hyperplasia. Adrenergic a 1 -receptor (a 1 -AR) blockers are widely used as first-line drugs in treating lower urinary tract symptoms resulting from BPH 1,2) because they are able to improve rapidly subjective symptoms by improving the functional obstruction.
Silodosin was approved in Japan for treating BPH (4 mg, bid) in January 2006, and was approved by the Food and Drug Administration (FDA, U.S.A.) for the same indication (8 mg, once a day (qd)) in October 2008. Currently, silodosin is under submission for registration with the China State Food and Drug Administration (SFDA) for treating BPH so clinical trials must be performed in the national clinical trial bases. The objectives of the present study were to assess the safety and pharmacokinetics of silodosin in Chinese subjects after oral administration.
MATERIALS AND METHODS
The study was approved by the Research Ethics Committee of Peking University First Hospital (Beijing, China) and the State Food and Drug Administration of China (2004L00051). It was conducted in accordance with Good Clinical Practices for Trials of Medicinal Products as well as the Declaration of Helsinki and its amendments. All subjects provided written informed consent before participation in the study.
Volunteers Eighty-two healthy male Chinese volunteers (aged 20-35 years old; body mass index, 19.0-27.0 kg/m 2 ) were included in this study. All subjects met the following criteria: nonsmokers with no clinical abnormalities based on clinical examinations and laboratory analyses. Subjects were excluded from the study for any of the following reasons: known hypersensitivity to any medications; conditions that might affect drug absorption, metabolism or excretion; untreated mental illness, current drug addiction, abuse or alcoholism; habitual daily coffee drinker; blood donation in the past 90 d; confirmed diagnosis of chronic liver disease (e.g., chronic hepatitis B, autoimmune disease); positive symptoms for human immunodeficiency virus; history of clinically significant cardiovascular, pulmonary, endocrine, neurological, metabolic or psychiatric disease; ingestion of any drug in the past 30 d; or being considered inappropriate for the study by an investigator. Signed informed consent stating that he was participating in this clinical trial on his own accord was obtained from each subject.
Study Design The study was designed to evaluate: (1) safety evaluations with a single-dosing escalation; (2) pharmacokinetic study with a single-dosing escalation; (3) safety and pharmacokinetic evaluations with multiple-dosing. The first and third evaluations were performed using a random-ized, double-blind, and placebo-controlled design. The second study was performed using a randomized but open design.
Silodosin capsules and matching placebo capsules were obtained from Daiichi Sankyo Corp. (Tokyo, Japan, formerly Daiichi Pharmaceuticals Co., Ltd.). The subjects lived in the clinical research unit during the study. Silodosin capsules and matching placebo capsules were orally administered together with 250 ml of warm drinking water.
Safety after a Single-Dosing Escalation Forty subjects were equally divided into four groups: 2 mg, 4 mg, 8 mg and 12 mg dosing groups. In each group, 8 of the subjects were administered silodosin once daily and two were given placebo once daily using a randomized and double-blind design. The subjects were fasted overnight (approximately 14 h) before administration in the morning. Standardized meals were served at specified times: lunch at 12:00 a.m., dinner at 5:00 p.m. and breakfast at 8:00 a.m. The subjects were discharged 2 h after breakfast on day 3.
Adverse events were judged according to the MedDRA Version 7.0 coding dictionary. During the study, the safety of silodosin was evaluated by clinical laboratory analyses, physical examinations, vital signs, electrocardiogram (ECG) measurements, and adverse event reports.
Blood and urine samples were collected for hematology and chemistry analyses at the screening stage and on day 2 before breakfast. The vital signs were assessed at the screening stage, and at 0 h (pre-dosing), 1 h, 2 h, 4 h, 6 h, 8 h, 24 h and 48 h post-dosing. ECGs were obtained at screening, and at 0 (pre-dosing), 1, 2, 4 and 24 h post-dosing.
Pharmacokinetics after a Single-Dosing Escalation Thirty subjects were equally divided into three groups: 4 mg, 8 mg and 12 mg dosing groups. The subjects were fasted overnight (approximately 14 h) before administration in the morning. Standardized meals were served at the specified times: lunch at 12:00 a.m., dinner at 5:00 p.m. and breakfast at 8:00 a.m.
Venous blood samples (approximately 7 ml) were collected in test tubes containing heparin sodium and 3(2)-tert-butyl-4-hydroxyanisole (BHA) at 0 h (pre-dosing), 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h and 36 h postdosing. Blood samples were centrifuged immediately at 3000 rpm at 4°C for 10 min, and stored at Ϫ20°C until LC-MS/MS measurement. Urine samples were collected 0-3 h, 3-6 h, 6-12 h, 12-24 h and 24-48 h post-dosing and stored at Ϫ20°C until LC-MS/MS measurement.
Safety and Pharmacokinetics after Multiple-Dosing In the multiple-dosing study, 10 of the 12 subjects were administered silodosin and two were given placebo using a randomized and double-blind design. Each subject was administered 4 mg silodosin or placebo once-daily on day 1 and day 7 after breakfast, and 4 mg silodosin twice daily on days 3, 4, 5, and 6 after breakfast and supper, respectively. Drinking water was allowed 2 h after dosing in the morning, and a standardized lunch was served 4 h after dosing.
To assess the safety, blood samples were collected for hematology and chemistry analyses prior to the study at the screening stage, on day 2 before breakfast, on day 7 before breakfast, and at a follow-up visit. The vital signs were assessed at screening, and 0 h (pre-dosing), 1 h, 2 h, 4 h, 6 h, 8 h, 24 h and 48 h post-dosing. ECGs were obtained at screening, and 0 h (pre-dosing), 1 h, 2 h, 4 h and 24 h postdosing.
To characterize the pharmacokinetics, venous blood samples were collected at 0 h (pre-dosing), and 0.25 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h (day 2 prior to morning dosing), 72 h (day 4 prior to morning dosing), 84 h (day 4 prior to evening dosing), 96 h (day 5 prior to morning dosing), 108 h (day 5 prior to evening dosing), 120 h (day 6 prior to morning dosing), and 132 h (day 6 prior to evening dosing). On day 7, venous blood samples were collected at 0 h (prior to dosing), and 0.25 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, 24 h and 36 h post-dosing. Blood samples were centrifuged immediately at 3000 rpm at 4°C for 10 min, and stored below Ϫ20°C until LC-MS/MS measurement. Urine samples were collected 0-12 h and 12-24 h postdosing on days 1, 4, 5, 6, 7 and 8 and were stored below Ϫ20°C until LC-MS/MS measurement.
Measurement of Silodosin Silodosin concentrations in plasma and urine samples were measured with a fully validated LC-MS/MS method (Hewlett-Packard system 1100 coupled with tandem mass spectrometry API 3000; MDS Sciex) after liquid-liquid extraction as reported previously.
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The lower limits of quantification for plasma and urine were 0.5 ng/ml and 1 ng/ml, respectively. The mean inter-day and intra-day precisions (RSD) were both less than 8%, and the mean recovery was in the range of 86.47-96.12%.
Calculations and Statistical Analyses The C max was the measured maximal concentration of silodosin, and the t max was the time to reach maximal concentration of silodosin obtained directly from the observed value. Plasma concentrations in the terminal phase for each subject were fit to a loglinear regression by the method of least squares to obtain the elimination rate constant (l Z ). The t 1/2 value was calculated with the following formula: t 1/2 ϭln(2)/l Z .
The AUC 0-36 values were the area under the concentration-time curve from 0 to 36 h calculated using the linear trapezoidal rule, and AUC 0-∞ values were calculated using the formula: AUC 0-∞ ϭAUC 0-36 ϩC last /l Z , where C last is the last measurable concentration. The C max and AUC 0-∞ values were normalized by dose: C max /D and AUC 0-∞ /D, respectively. Apparent clearance (CL/F) was calculated by dose/AUC 0-∞ , and apparent volume of distribution (V z /F) was calculated by CL/F/l Z . After the multiple-dosing administrations, the accumulation ratio of R A was calculated by comparing the AUC 0-24 after the last dosing on day 7 with the AUC 0-24 after the first dosing on day 1.
The cumulative amount of drug excreted in urine (A e ) was calculated using the urine volume and drug concentration measurements. The fraction of drug excreted unchanged in the urine ( f e ) was calculated with the formula: f e ϭA e /dose.
Data are presented as the meanϮstandard deviation. Oneway analysis of variance was used to determine the significance of C max /dose or AUC 0-36 /dose values among groups in the single-dosing study after dose normalization. A value of pϽ0.05 was considered to be significant.
RESULTS

Demographic Characteristics and Laboratory Analyses
Eighty-two healthy Chinese male subjects were enrolled in this study. Their ethnic backgrounds were 79 Han, 1 Dong, 1
Manchu and 1 Hui. Seventy-two subjects were orally administered silodosin capsules and 10 were administered blank placebo. There was no withdrawal due to either noncompliance or protocol violation. Table 1 shows the demographic data of the subjects. For all subjects, the age was in the range of 19-26 years old; the height was in the range of 160-180 cm; the body weight was in the range of 54-73 kg; and the BMI was in the range of 19-25 kg/m 2 . Laboratory analyses demonstrated that the blood and urine indicators of the subjects were in the normal range (data not shown).
Safety Observations after Single-Dosing Escalation and Multiple-Dosing Table 2 shows the adverse events observed in the single-dosing escalation and multiple-dosing administrations. The main adverse reactions and laboratory abnormalities observed included face pyrexia; nervous system abnormalities; general fatigue of limbs; abnormal triglyceride levels; headache; headache and nausea; dizziness; nasal congestion; intraocular foreign body sensation; postural hypotension; total bilirubin (TBIL) elevation; alanine aminotransferase (ALT) elevation; creatine kinase (CK) elevation; hematuria; and abnormal urine leukocytes. All adverse events were associated with orally administered silodosin capsules. In the low dose groups, no adverse events were observed in the 2 mg dose group and only 1 adverse event was found in the 4 mg group. In the high dose groups, the incidences of adverse events observed in the 8 mg and 12 mg group were 50% and 63%, respectively. In the placebo control group, 25% of the subjects also suffered from adverse events that included facial pyrexia and abnormal triglyceride levels. A total of 17 adverse events were reported in 11 subjects in the single-dosing escalation study. Nevertheless, all adverse events were mild and tolerable, and were associated with silodosin. None of the subjects required treatment, and most of the adverse episodes had improved by the end of the study, showing that all subjects tolerated the formulations well and indicating compliance was good.
In the multiple-dosing study, a total of 3 adverse events were observed in 2 subjects. The adverse reactions included elevated levels of TBIL and ALT. All adverse events were similarly mild and tolerable. None of the subjects required treatment, and most of the adverse episodes had improved by the end of the study.
Pharmacokinetics after Single-Dosing Figure 1 shows the plasma concentration-time profiles of silodosin in the single-dosing escalation study after oral administration at a dose of 4 mg, 8 mg, and 12 mg, respectively. The results showed that the area of the concentration-time curve had increased with the dose escalation in a dose-dependent manner. After oral administration of the capsule form, silodosin was absorbed rapidly, and exhibited two maximal absorption peaks in the profile. Table 3 shows the pharmacokinetic parameters of silodosin. After oral administration of silodosin at a dose of 4 mg, 8 mg and 12 mg, the mean C max values were 26.70 mg/l, 48.47 mg/l and 94.07 mg/l, and the AUC 0-36 values were a) n (%) represents the number of subjects and the incidence (%); TBIL, total bilirubin; CK, creatine kinase; ALT, alanine aminotransferase.
136.82 mg/l · h, 270.17 mg/l · h, and 474.63 mg/l · h, respectively. In all dose groups, the median values of t max were in the range of 1.5-2 h; the mean values of t 1/2 were in the range of 4.6-5.9 h; the CL/F values were in the range of 25.8 to 31.5 l/h; and the V z /F values were in the range of 207.5-224.2 l. After dose normalization, there were no statistically significant differences in the C max /dose or in the AUC 0-36 /dose values among groups (pϾ0.05). In addition, after oral administration at a dose of 4 mg, 8 mg and 12 mg, the urine excretion rates of silodosin within 48 h were 3.43%, 2.98% and 3.37%, respectively.
Pharmacokinetics after Multiple-Dosing Figure 2 shows the plasma concentration-time profiles of silodosin after one time dosing at day 1, and those after the last dosing at day 7. The results showed that the area under the concentration-time curve at day 7 was bigger than that at day 1. Similarly, silodosin was absorbed rapidly after dosing either as a single dose or multiple doses. Table 4 shows the pharmacokinetic parameters of silodosin after one dosing at day 1, and the parameters of silodosin after the last dosing at day 7 following twice daily multiple oral administrations. After administration of one dose on day 1 and the last one dose on day 7 through multiple doses, the median values of t max were all 2 h, and the values of CL/F and V z /F were similar, however, the mean values of t 1/2 were 6.25 h and 8.03 h, the mean values of C max were 23.47 mg/l and 33.84 mg/l, and the mean values of AUC 0-24 were 134.82 mg/l · h and 193.19 mg/l · h, respectively. Following 5 d of twice daily dosing, the accumulation ratio was 1. 55  (1.45-1.66) . The urinary excretion fractions of silodosin (f e ) at day 1 and at day 7 were 2.98% and 3.69%, respectively.
As for the trough concentrations during the multiple doses, the mean C min values were 5.13 mg/l at 72 h (day 4), 4.20 mg/l at 84 h (day 4), 5.24 mg/l at 96 h (day 5), 5.02 mg/l at 108 h (day 5), 5.02 mg/l at 120 h (day 6), 4.95 mg/l at 132 h (day 6), and 4.73 mg/l at 144 h (day 7). C max , maximal silodosin concentration in plasma; C max /D, value after dose normalization, i.e. C max divided by dose; t max , time to reach maximal silodosin concentration in plasma; t 1/2 , half-life of elimination; AUC 0-36 , area under the concentrationtime curve from 0 to 36 h; AUC 0-∞ , area under the concentration-time curve from 0 h to infinity; AUC 0-36 /D, a value after dose normalization; CL/F, total body clearance; V z /F, apparent volume of distribution; f e , fraction of drug excreted in urine in the unchanged form. In the study, each subject orally received silodosin once daily at day 1 or at day 7, while each received silodosin twice daily during the multiple administrations from day 2 to day 6. Each dose was at 4 mg of silodisin. AUC 0-24 , area under the concentration-time curve from zero to 24 h; R A , accumulation ratio (AUC 0-24 at day 7/AUC 0-24 at day 1)
DISCUSSION
The aim of the present clinical trial performed in healthy Chinese subjects was to evaluate the safety and pharmacokinetics of silodosin capsules in a single-dose escalation and in multiple doses. No serious adverse events were observed in any group. All subjects were in good compliance and they tolerated the drug at the levels given. The three most frequently reported treatment-emergent adverse events, which were dizziness, headache and TBIL elevation, were experienced by the subjects following administration at a high dose of 8 mg or 12 mg. The adverse events were due to the dose escalation of silodosin and were reversible after drug discontinuation. These typical adverse events have been also experienced in Japanese 9) and white subjects.
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Vasodilatory side effects such as dizziness and postural hypotension have been encountered in both Japanese and Chinese subjects, and such adverse events are typical and well-recognized effects of drugs targeting a 1 -AR, due to their pharmacological inhibition of reflex blood pressure. 12) However, gastrointestinal side effects like soft feces and diarrhea were observed in Japanese subjects but were not observed in the Chinese subjects in the present study. In addition to age, the disease state, food consumed during drug administration, and the numbers of patients may have influenced the observed results related to the incidence of gastrointestinal adverse events like soft stools and diarrhea among the studies in Japan, America and China. Gastrointestinal adverse events should be further observed in future clinical trials with larger patient populations.
In the clinical phase III studies performed in Japan and the United States, one of the major adverse events was retrograde ejaculation. However, all subjects enrolled in this study were unmarried male college students, and the entire study was performed in the hospital phase I ward from 1 d before administration to the end of the research, and none of them reported this adverse event. Retrograde ejaculation and other adverse events will be further observed in phase II and III trials.
Silodosin capsules were rapidly absorbed within 1-2 h after oral administration, and two absorption phases were observed in the single-dosing escalation study in which the plasma concentration-time curves of more than 50% of the subjects had two absorption peaks. Results from a study in rats revealed that silodosin underwent biliary excretion and enterohepatic circulation, 13) and these phenomena may cause the re-absorption of silodosin in the intestinal tract. A possible reason could be the powders of silodosin are distributed to different sites after disintegration of the capsules in the gastrointestinal tract, thereby resulting in the delay of absorption and the dual-peaks of absorption.
In the single-dosing escalation study, the AUC values increased in proportion with the increase in silodosin dose, demonstrating that silodosin exhibited characteristics of linear rather than nonlinear pharmacokinetics. Accordingly, the C max values changed in a linear manner with adjustment of doses, and after dose normalization, the C max /dose or AUC/dose value tended to be the same value among the dose groups.
In the multiple-dosing study, silodosin at steady-state showed an accumulation in some extents after oral dosing twice-daily, and consequently, the C max or AUC value at steady-state was enhanced corresponding to the accumulation ratio (approximately 1.55 fold). After multiple doses, the time to reach maximal concentration had not been affected but the elimination half-life was slightly extended by 2 h (6 h versus 8 h). The latter phenomenon may be caused by the accumulation of silodosin in tissues, and a continuous release of silodosin binding with the tissue proteins and other ingredients resulted in the extended elimination.
In order to fully compare the pharmacokinetics of silodosin in Chinese with that in Japanese (only reported previously in Japan), Table 5 shows a comparison between the major pharmacokinetic parameters in Chinese and Japanese subjects based on single-dosing and multiple-dosing. In an overall estimation, the pharmacokinetic profiles of silodosin in Chinese and Japanese subjects are similar in terms of parameters such as AUC, C max , t max and t 1/2 values. 14) The low excretion rate of silodosin in the urine in the first 48 h after single or multiple-dosing indicated that the excretion by urine was not the major metabolism route of silodosin. This is consistent with previous results indicating that silodosin was mainly metabolized in the liver and excreted through the feces after oral administration. 13) In summary, silodosin is safe and well tolerated in healthy Chinese subjects following single-dosing escalation once daily in the dose range of 2-12 mg, and multiple-dosing twice daily (4 mg per administration). Mild adverse events like headache, dizziness, and TBIL elevation are frequently encountered and are related to dose escalation but reversible after drug discontinuation. The drug is absorbed rapidly and reaches the maximal concentration 1-2 h after oral administration. The mean maximal and mean trough concentrations after single or multiple-dosing (4 mg per administration, once or twice daily) are approximately 20-35 mg/l, and 4-6 mg/l, respectively. The half-life of elimination is in the range of 4-8 h, depending on whether the dosing is single or multiple. The mean C max and AUC values of silodosin increase in proportion with dose escalation, showing characteristics of linear pharmacokinetics. The accumulation ratio in the steady-state after oral administration twice daily is approximately 1.5 fold. (mg · h/l) Data are presented as the meanϮstandard deviation. C max,ss , the mean maximal concentration at steady-state concentration. a) Median. b) AUC 0-24 , area under the concentration-time curve from zero to 24 h. c) AUC 0-48 , area under the concentrationtime curve from zero to 48 h.
